ClinicalTrials.gg
CompletedNCT00399035HORIZON IIUpdated Dec 28, 2016Results posted

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

A Phase 3 interventional study of Cediranib and FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer, sponsored by AstraZeneca. Completed at 91 sites in 15 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-12-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,254
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing Folfox protocol in Colorectal Neoplasms — 14 open to participants now, 17 under way, 3 of them phase 3. Folfox protocol · Colorectal Neoplasms.

Enrollment
3rd of 37
1,254 · median 102
Started
2006
the only one that year
Phase 3
7 of 37
1 open now
Registered
3rd of 37
by date
Lead sponsor
1 of 37
AstraZeneca

Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2006, is one of 7 in phase 3, and was the 3rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

14 of the 37 studies testing Folfox protocol in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Folfox protocol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing Folfox protocol in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal cancer.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Colorectal Cancer
  • Cediranib
  • RECENTIN
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Carcinoma of the colon or rectum
  • One or more

Exclusion criteria

Exclusion Criteria:

  • /neoadjuvant therapy within 6-12 months of study entry
  • Untreated unstable brain or meningeal
  • Specific laboratory ranges
  • Specific cardiovascular problems
  • Participation in other trials within 30 days
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,254 participants (actual)

Study arms

  • Placebo comparator
    FOLFOX + placebo Cediranib

    FOLFOX + placebo Cediranib

    Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) · Drug: Cediranib Placebo

  • Placebo comparator
    Xelox + placebo Cediranib

    Xelox + placebo Cediranib

    Drug: XELOX (Capecitabine and Oxaliplatin) · Drug: Cediranib Placebo

  • Experimental
    FOLFOX + Cediranib

    FOLFOX + Cediranib

    Drug: Cediranib · Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)

  • Experimental
    XELOX + Cediranib

    XELOX + Cediranib

    Drug: Cediranib · Drug: XELOX (Capecitabine and Oxaliplatin)

Interventions

  • oral tablet

    Also known as: AZD2171, RECENTIN™

  • intravenous infusion

    Also known as: Other Names:, 5-FU, Drug: Leucovorin (in FOLFOX), intravenous infusion, Drug: Oxaliplatin (in FOLFOX), Eloxatin®

  • DrugXELOX (Capecitabine and Oxaliplatin)

    Drug page: Xelox

    intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)

    Also known as: Xeloda® + Eloxatin®

  • DrugCediranib Placebo

    oral tablet

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression \[non-PD\]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions.

    Time frame: RECIST assessed at baseline every 6 weeks through to week 24 and 12 week thereafter through to progression or data cut off date of 21/03/10 whichever was earliest.

  2. Overall Survival

    Number of months from randomisation to the date of death from any cause

    Time frame: Baseline through to date of death upto and including data cut off date of 21/03/10

Secondary outcomes

  1. Overall Response Rate

    Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi

    Time frame: Baseline through to date of death upto and including data cut off date of 21/03/10

  2. Best Percentage Change in Tumour Size

    Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions

    Time frame: Baseline through to date of death upto and including data cut off date of 21/03/10

  3. Duration of Response

    Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies.

    Time frame: Treatment period from initial response up until data cut-off date of 21/03/10

  4. Rate of Resection of Liver Metastases

    Number of patients undergoing liver resection, based on patients with liver disease at baseline

    Time frame: Post-randomisation until end of study

  5. Time to Wound Healing Complications

    Number of days from post-randomisation surgery until wound healing complications

    Time frame: Post-randomisation until end of study

07

Results

Posted Oct 30, 2012

Participant flow

Randomised=full analysis set: Cediranib 20mg=502, Placebo=358; Safety set: Cediranib 20mg=500, Cediranib 30mg=214, Placebo=358

Participant flow — Overall Study
MilestoneCediranib 20 mg/DayCediranib 30 mg/DayPlacebo
Started502216358
Completed18958106
Not completed313158252
Withdrew: Death289141234
Withdrew: Lost to follow-up215
Withdrew: Withdrawal by subject191512
Withdrew: Incorrect enrolment/eligib not fulfilled101
Withdrew: Severe non-compliance with protocol210

Outcome measures

PrimaryProgression-free Survival

RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression \[non-PD\]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions.

Time frame:
RECIST assessed at baseline every 6 weeks through to week 24 and 12 week thereafter through to progression or data cut off date of 21/03/10 whichever was earliest.
Reported as:
Median · Months
Progression-free Survival
MonthsCediranib 20 mgPlacebo
Progression-free Survival8.6 (5.5 to 12.1)8.2 (4.1 to 11.1)
PrimaryOverall Survival

Number of months from randomisation to the date of death from any cause

Time frame:
Baseline through to date of death upto and including data cut off date of 21/03/10
Reported as:
Median · Months
Overall Survival
MonthsCediranib 20 mgPlacebo
Overall Survival19.7 (11.0 to 36.1)18.9 (11.0 to 28.9)
SecondaryOverall Response Rate

Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi

Time frame:
Baseline through to date of death upto and including data cut off date of 21/03/10
Reported as:
Number · Participants
Overall Response Rate
ParticipantsCediranib 20 mgPlacebo
Overall Response Rate254178
SecondaryBest Percentage Change in Tumour Size

Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions

Time frame:
Baseline through to date of death upto and including data cut off date of 21/03/10
Reported as:
Mean · Percentage [change in tumour size (mm) ]
Best Percentage Change in Tumour Size
Percentage [change in tumour size (mm) ]Cediranib 20 mgPlacebo
Best Percentage Change in Tumour Size-42.49 ± 28.139-40.61 ± 31.992
SecondaryDuration of Response

Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies.

Time frame:
Treatment period from initial response up until data cut-off date of 21/03/10
Reported as:
Median · Months
Duration of Response
MonthsCediranib 20 mgPlacebo
Duration of Response8.5 (5.9 to 12.7)6.9 (4.8 to 11.0)
SecondaryRate of Resection of Liver Metastases

Number of patients undergoing liver resection, based on patients with liver disease at baseline

Time frame:
Post-randomisation until end of study
Reported as:
Number · Participants
Rate of Resection of Liver Metastases
ParticipantsCediranib 20 mgPlacebo
Rate of Resection of Liver Metastases2117
SecondaryTime to Wound Healing Complications

Number of days from post-randomisation surgery until wound healing complications

Time frame:
Post-randomisation until end of study
Reported as:
Median · Days
Time to Wound Healing Complications
DaysCediranib 20 mgPlacebo
Time to Wound Healing Complications18 (1 to 93)18 (0 to 114)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cediranib 30mg—94/214 (43.9%)209/214 (97.7%)
Cediranib 20mg—204/500 (40.8%)485/500 (97%)
Placebo—105/358 (29.3%)341/358 (95.3%)
Most frequent serious events
Showing 10 of 240
Most frequent serious events
EventCediranib 30mgCediranib 20mgPlacebo
DiarrhoeaGastrointestinal disorders14/21434/50011/358
DehydrationMetabolism and nutrition disorders8/21414/5007/358
HypertensionVascular disorders8/2146/5002/358
VomitingGastrointestinal disorders5/2147/5008/358
Renal FailureRenal and urinary disorders5/2143/5000/358
PneumoniaInfections and infestations3/2147/5008/358
ThrombocytopeniaBlood and lymphatic system disorders0/21411/5007/358
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders4/21410/5004/358
Febrile NeutropeniaBlood and lymphatic system disorders4/2144/5003/358
Intestinal ObstructionGastrointestinal disorders3/2148/5004/358
Most frequent other events
Showing 10 of 55
Most frequent other events
EventCediranib 30mgCediranib 20mgPlacebo
DiarrhoeaGastrointestinal disorders147/214346/500165/358
NauseaGastrointestinal disorders92/214256/500169/358
VomitingGastrointestinal disorders83/214230/500126/358
Decreased AppetiteMetabolism and nutrition disorders92/214229/500125/358
HypertensionVascular disorders96/214226/50041/358
FatigueGeneral disorders80/214200/500104/358
Peripheral Sensory NeuropathyNervous system disorders45/214141/50089/358
ThrombocytopeniaBlood and lymphatic system disorders56/214139/50084/358
NeutropeniaBlood and lymphatic system disorders49/214138/50075/358
StomatitisGastrointestinal disorders59/214118/50048/358

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cediranib 20 mgPlaceboCediranib 30 mgTotal
Mean57.8 ± 11.1457.2 ± 11.6359.4 ± 10.6957.6 ± 11.34
Gender
Gender(Participants)Cediranib 20 mgPlaceboCediranib 30 mgTotal
Female20314693442
Male299212123634
08

Study locations

91 sites
  • Research Site
    Buenos Aires City, Argentina
  • Research Site
    Capital Federal, Argentina
  • Research Site
    Ciudad de Buenos Aires, Argentina
  • Research Site
    Córdoba, Argentina
  • Research Site
    Resistencia, Argentina
  • Research Site
    Rosario, Argentina
  • Research Site
    Santa Fe, Argentina
  • Research Site
    Ashford, Australia
  • Research Site
    Camperdown, Australia
  • Research Site
    Heidelberg, Australia
  • Research Site
    Hornsby, Australia
  • Research Site
    Liverpool, Australia
  • Research Site
    Waratah, Australia
  • Research Site
    Wodonga, Australia
  • Research Site
    Curitiba, Brazil
  • Research Site
    Goiânia, Brazil
  • Research Site
    Jaú, Brazil
  • Research Site
    Porto Alegre, Brazil
  • Research Site
    Rio de Janeiro, Brazil
  • Research Site
    Salvador, Brazil
  • Research Site
    Santo André, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    São Paulo, Brazil
  • Research Site
    Plovdiv, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Stara Zagora, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Veliko Tarnovo, Bulgaria
  • Research Site
    Vratza, Bulgaria
  • Research Site
    Beijing, China
  • Research Site
    Changchun, China
  • Research Site
    Chengdu, China
  • Research Site
    ChongQing, China
  • Research Site
    Fuzhou, China
  • Research Site
    Guangzhou, China
  • Research Site
    Hangzhou, China
  • Research Site
    Nanjing, China
  • Research Site
    Nanning, China
  • Research Site
    Shanghai, China
  • Research Site
    Tianjin, China
  • Research Site
    Brno, Czech Republic
  • Research Site
    Ceske Budejovice, Czech Republic
  • Research Site
    Cheb, Czech Republic
  • Research Site
    Jicin, Czech Republic
  • Research Site
    Jihlava, Czech Republic
  • Research Site
    Olomouc, Czech Republic
  • Research Site
    Ostrava, Czech Republic
  • Research Site
    Praha 6, Czech Republic
  • Research Site
    Pribram - Zdabor, Czech Republic
  • Research Site
    Sumperk, Czech Republic
  • Research Site
    Zlin, Czech Republic
  • Research Site
    Znojmo, Czech Republic
  • Research Site
    Essen, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Goslar, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Hildesheim, Germany
  • Research Site
    Mannheim, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Györ, Hungary
  • Research Site
    Kecskemét, Hungary
  • Research Site
    Nyíregyháza, Hungary
  • Research Site
    Szombathely, Hungary
  • Research Site
    Zalaegerszeg, Hungary
  • Research Site
    Hyderabad, India
  • Research Site
    Trivandrum, India
  • Research Site
    Goyang-si, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Cebu City, Philippines
  • Research Site
    Davao City, Philippines
  • Research Site
    Iloilo, Philippines
  • Research Site
    Quezon City, Philippines
  • Research Site
    Quezon, Philippines
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Gdańsk, Poland
  • Research Site
    Gliwice, Poland
  • Research Site
    Kraków, Poland
  • Research Site
    Olsztyn, Poland
  • Research Site
    Toruń, Poland
  • Research Site
    Wrocław, Poland
  • Research Site
    Bellinzona, Switzerland
  • Research Site
    Lausanne, Switzerland
  • Research Site
    Locarno, Switzerland
  • Research Site
    Zürich, Switzerland
  • Research Site
    Tainan, Taiwan
  • Research Site
    Taipei, Taiwan
  • Research Site
    Aberdeen, United Kingdom
  • Research Site
    Belfast, United Kingdom
  • Research Site
    Leicester, United Kingdom
  • Research Site
    Manchester, United Kingdom
09

References and documents

Publications

  • Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jurgensmeier JM. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. Eur J Cancer. 2013 Jul;49(10):2424-32. doi: 10.1016/j.ejca.2013.02.023. Epub 2013 Mar 16. PubMed 23510802 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Mar 2010 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 2 years 7 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2006
First posted
Nov 14, 2006
Start
Nov 2006
Primary completionActual
Mar 2010
CompletionActual
Aug 2016
Results delay requested
Apr 6, 2011
Results first posted
Oct 30, 2012
Last update
Dec 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00399035
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 14, 2006
Start date
Nov 2006
Primary completion
Mar 2010
Completion
Aug 2016
Results posted
Oct 30, 2012
Last update
Dec 28, 2016

Study contacts

Jane Robertson
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cediranib · Folfox protocol · Xelox

Start the discussion